Search results
Added:
5 years ago
Diego Ardissino discusses PHARMCLO -Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes.
Filmed by Radcliffe Cardiology on-site at the ACC 2018 congress in Orlando, US.
View more
Added:
2 years ago
Dr. Hirotoshi Watanabe (Kyoto University Graduate School of Medicine, JP) discusses the results of the STOPDAPT-2 ACS study. The aim of this study was to assess the safety of reducing dual antiplatelet therapy (DAPT) duration to 1-month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
The trial showed that in ACS…
View more
Added:
3 years ago
Introduction
Antiplatelet therapy is a cornerstone in coronary artery disease (CAD) management. Acetylsalicyclic acid (ASA) has been known for many decades to have antithrombotic efficacy. Already in the 1980’s, the ISIS-2 study demonstrated that ASA reduces mortality in acute myocardial infarction (AMI) by 23 %.1 ASA leads to irreversible inactivation of cyclooxygenase 1 and thereby blocks the…
View more
Added:
3 years ago
Acute coronary syndromes (ACS) result from unstable coronary artery plaques that rupture and can lead to coronary ischaemia, unstable angina and myocardial infarction. The treatment goals in ACS focus on reducing ischaemia, preventing further progression of thrombotic plaque by disturbing the milieu of thrombosis and platelet aggregation taking place within the coronary artery and, in the case of…
View more
Added:
3 years ago
Antiplatelet Therapy
Current guidelines support the early administration of oral antiplatelet agents upstream of angiographic assessment and intervention.1 Aspirin is commonly given by the first medical contact and additional oral antiplatelet drugs are administered on arrival in hospital (see Figure 1).
Aspirin
The efficacy of aspirin in acute ST-segment elevation myocardial infarction (STEMI)…
View more
Added:
3 years ago
Currently, attention is focused on the therapeutic use of P2Y12 receptor antagonists in patients with cardiovascular pathologies, especially during and following coronary interventions. Such drugs inhibit platelet aggregation brought about by adenosine diphosphate (ADP), which plays a central role in platelet function.1 ADP activates platelets via two specific receptors on the platelet surface,…
View more
Added:
3 years ago
The role of platelets in coronary artery thrombosis is well-established.1 They also play a critical role in a number of cardiovascular conditions including stroke, peripheral vascular disease and diabetes, and may be involved in the pathology underlying atherosclerotic changes.1 Antiplatelet agents such as clopidogrel, a platelet P2Y12 receptor antagonist, and aspirin are used for the prevention…
View more
Added:
3 years ago
Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable…
View more
Added:
3 years ago
Dual antiplatelet therapy (DAPT) is indicated in patients who need to undergo percutaneous coronary intervention (PCI) procedures.1 Compared with oral anticoagulation (OAC) and aspirin, DAPT has been shown to reduce the risk of thrombotic events and the rate of bleeding events.2 Chronic OAC is required in up to 10 % of the patients undergoing PCI, and is usually indicated for AF and mechanical…
View more
Added:
3 years ago
Valvular Heart Surgery
The field of cardiac surgery is urgently in need of new anticoagulant agents. Approximately 300,000 prosthetic valves are implanted yearly, after which lifelong anticoagulation therapy is mandatory as thromboprophylaxis. To date, vitamin K antagonists (VKAs), such as warfarin, remain the only licensed agents to prevent mechanical valve-induced thromboembolic events but…
View more
